By Budi Oetomo Narendra 
Breast cancer screening, a cornerstone of public health efforts aimed at reducing mortality from the disease, has long grappled with a complex phenomenon known as overdiagnosis. This occurs when screening identifies cancers that, if left undetected, would never have progressed to cause symptoms, threaten a woman’s health, or shorten her life. For decades, the extent of this overdiagnosis has been a subject of intense scientific debate, with significant implications for screening guidelines, public perception, and the peace of mind of millions of women worldwide. Recent collaborative research, however, offers a substantial re-evaluation of previous estimates, suggesting that the incidence of overdiagnosis may be far lower than once widely cited figures, potentially reshaping the discourse around the benefits and harms of mammography screening.
The controversy surrounding overdiagnosis stems from the very success of screening programs: their ability to detect cancers at earlier stages. While this early detection is crucial for improving prognosis for aggressive cancers, it also inevitably uncovers indolent lesions that might never have become clinically significant. The challenge lies in distinguishing between these two categories. Historically, estimates derived from some randomized controlled trials (RCTs) have fueled concerns, suggesting that as many as 30-50% of breast cancers detected through screening could be overdiagnosed. These figures have permeated international health discussions, influencing policy recommendations and contributing to a narrative that sometimes overshadowed the life-saving benefits of screening.
A pivotal new study, spearheaded by researchers from the University of Southern Denmark, Lillebælt Hospital, University of Copenhagen, and Queen Mary University of London, aimed to provide a clearer, more robust picture of overdiagnosis by comprehensively re-analyzing existing evidence. "The aim of our study was to bring together the evidence from all randomized controlled trials to get a clearer picture of the extent of overdiagnosis in breast cancer screening," states Sisse Helle Njor, a professor at the University of Southern Denmark and Lillebælt Hospital. She emphasizes the nuanced nature of their findings: "Randomized trials have often been cited as evidence that overdiagnosis is a substantial problem. Our study shows that this interpretation is not as straightforward as it may seem." The researchers’ conclusions represent a significant departure from earlier, higher estimates, suggesting that overdiagnosis associated with screening is likely below 5%.
The Overdiagnosis Conundrum: A Historical Perspective
The concept of overdiagnosis in cancer screening is not unique to breast cancer. It is a recognized challenge in prostate cancer (PSA screening) and thyroid cancer, for instance. However, its prevalence in breast cancer screening has been particularly contentious due to the widespread nature of mammography programs and the significant emotional and physical toll of a breast cancer diagnosis and subsequent treatment.
The debate gained considerable traction with the publication of various analyses of long-running randomized controlled trials that began in the 1960s and 70s. These trials, designed to assess the efficacy of mammography in reducing breast cancer mortality, provided the initial data points for estimating overdiagnosis. When a screening program is introduced, a surge in cancer diagnoses is typically observed. This "incidence peak" is partly due to the earlier detection of cancers that would eventually become symptomatic (lead time bias), and partly due to the detection of cancers that would never progress. Distinguishing between these two components, especially in the relatively early follow-up periods of the trials, proved challenging.
The perceived high rates of overdiagnosis (30-50%) led to considerable anxiety among women invited for screening and prompted calls for revised guidelines that emphasized shared decision-making, where women would be fully informed of both the benefits (mortality reduction) and potential harms (overdiagnosis, false positives, anxiety, unnecessary biopsies/treatments). The concern was that a woman might undergo surgery, radiation, or chemotherapy for a cancer that posed no actual threat to her life, incurring significant physical, psychological, and financial burdens without any health benefit.
A Deeper Dive into Methodologies: Re-evaluating Evidence
To address the ambiguities, the research team undertook a comprehensive new analysis, combining and re-evalyzing results from all eight randomized controlled trials of mammography screening. These included foundational studies such as the New York Health Insurance Plan (HIP), Malmö, Two-County, Edinburgh, the Canadian National Breast Screening Study (CNBSS), Stockholm, Gothenburg, and UK Age. These trials represent decades of data collection involving hundreds of thousands of women across different healthcare systems.
Crucially, the team then compared these re-analyzed trial results with real-world data from Denmark. Denmark offered a unique and valuable reference point due to its staggered implementation of organized breast cancer screening. In some regions, screening began as much as 17 years earlier than in others. This chronological difference allowed researchers to meticulously track the evolution of breast cancer diagnosis patterns immediately after screening introduction and over extended periods, providing a natural experiment to observe the long-term effects of screening in a population context.
Elsebeth Lynge, professor emerita at the Department of Public Health, University of Copenhagen, elaborated on the complexities of interpreting early screening data: "When screening is introduced, the number of breast cancer diagnoses initially rises because cancers are detected earlier than they would have been without screening. Over time, this should be followed by a drop, as some of these cancers would otherwise have been diagnosed later. This pattern can also be affected if women in either group continue to undergo screening after the trials had ended, which was common. If researchers do not take these factors into account, the initial increase can be mistaken for overdiagnosis."
The researchers focused on three critical factors known to influence overdiagnosis estimates when reassessing the earlier trials:
- Lead Time Bias: The period by which a diagnosis is advanced by screening.
- Length Bias: The disproportionate detection of slower-growing cancers by screening.
- Contamination: When women in the control groups of trials later receive screening themselves, blurring the distinction between screened and unscreened populations.
- Incomplete Follow-up: If studies conclude before the full "catch-up" effect (the eventual decline in diagnoses in the screened group due to earlier detection) is observed, the initial incidence peak can be misinterpreted.
By meticulously accounting for these differences in screening exposure, follow-up duration, and the natural progression of cancer incidence over time, the researchers were able to align the observed patterns in the randomized trials with the real-world experience of the Danish screening programs. This rigorous approach allowed them to disentangle the true extent of overdiagnosis from other confounding factors.
The Crucial Role of Timing and Full Temporal Context
The timing of data collection and analysis proved to be a critical element in the re-evaluation. When mammography screening is first implemented, there is an unavoidable surge in detected cancers. This initial rise is a combination of true early detection (which benefits women) and overdiagnosis. If a study’s follow-up period is too short, or if the analysis is conducted before the "incidence dip" – the subsequent reduction in diagnoses that should occur as cases that would have been diagnosed later are now detected earlier – becomes apparent, then a significant portion of this initial rise can be erroneously attributed to overdiagnosis.
Matejka Rebolj, Senior Epidemiologist at Queen Mary University of London, underscored this point: "Taken together, we believe some previous high estimates of overdiagnosis, which influenced screening guidelines and communication, were based on evidence before trial data had fully matured. When interpreted in their full temporal context, randomized trial data are consistent with overdiagnosis of less than five percent, rather than with estimates nearing 50%."
The new analysis demonstrated that when these timing effects, particularly the crucial "catch-up" period where incidence rates in screened groups should eventually fall below or match those in unscreened groups, are fully incorporated, the picture of overdiagnosis changes dramatically. The patterns observed in the trials, when viewed over their full temporal context, closely mirrored the incidence trends in Denmark, where overdiagnosis is estimated to be below 5%. This suggests a much smaller fraction of screen-detected cancers are truly overdiagnosed, moving the needle from potentially half of all screened-detected cancers to less than one in twenty.
Significantly Revised Estimates and Their Implications
The study’s finding that overdiagnosis is likely below 5% represents a paradigm shift in the understanding of breast cancer screening harms. This revised estimate stands in stark contrast to the 30-50% figures that have long shaped public discourse and clinical guidelines. The implications are profound and far-reaching for public health policy, patient counseling, and the broader perception of mammography.
For public health authorities and policymakers, these findings offer a clearer evidence base for optimizing screening programs. It reinforces the significant net benefit of mammography in reducing breast cancer mortality, suggesting that the previously perceived "harm" of overdiagnosis is much smaller than previously feared. This could lead to a renewed emphasis on the importance of regular screening and potentially influence decisions on screening ages and intervals.
Patient advocacy groups, which have often had to balance the benefits of early detection with the risks of overdiagnosis when advising women, now have stronger evidence to present. The message that "the benefits of detecting breast cancer early and preventing premature death will outweigh the small risk of unnecessary treatment" can be delivered with greater confidence. This is particularly important for women contemplating participation in screening programs, as it can alleviate some of the anxiety associated with the possibility of overdiagnosis.
Moreover, the study examined both invasive breast cancer and ductal carcinoma in situ (DCIS), a non-invasive condition often detected by mammography. DCIS is sometimes referred to as "stage 0" breast cancer, where abnormal cells are confined to the milk ducts. While some DCIS lesions can progress to invasive cancer, many never will, making it a key area of concern for overdiagnosis. The new analysis’s comprehensive approach to both types of breast cancer strengthens its conclusions.
Expert Perspectives and Future Outlook
The researchers involved in this study express hope that their work will provide a more realistic framework for interpreting the evidence surrounding breast cancer screening. Sisse Helle Njor articulated this sentiment: "With this in mind, we hope this study will provide a framework for a more realistic interpretation of the evidence and help us better inform women when they are invited for screening." This objective is crucial for fostering trust between healthcare providers and the public, ensuring that women make informed decisions based on the most accurate and up-to-date scientific understanding.
The funding for this research, provided by institutions like the Novo Nordisk Foundation and Cancer Research UK, highlights the importance placed on resolving this long-standing debate. Such investment underscores the commitment within the scientific community to continually refine our understanding of complex medical interventions and their societal impact.
While this study offers significant reassurance, it does not negate the importance of ongoing research into personalized screening approaches. Identifying biomarkers or imaging techniques that can more accurately distinguish between aggressive cancers and indolent lesions remains a critical goal. This would further reduce the risk of overdiagnosis and overtreatment, tailoring screening recommendations to individual risk profiles.
In conclusion, the re-evaluation of randomized controlled trials and the comparison with real-world Danish data offer a compelling argument that breast cancer overdiagnosis, while a genuine phenomenon, occurs at a substantially lower rate than previously estimated. This new understanding strengthens the case for population-based mammography screening as a vital tool in cancer control, providing greater clarity for healthcare providers and renewed reassurance for women making critical health decisions. The decades-long debate on breast cancer overdiagnosis appears to be shifting towards a more optimistic perspective, reinforcing the net benefits of early detection in the fight against breast cancer.
